Glucose Metabolism Disorders among People Living with HIV/AIDS on Efavirenz and Atazanavir/Ritonavir-Based Combination Antiretroviral Therapy: A Pharmacogenetic and Pharmacokinetic Evaluation
| dc.contributor.advisor | Engidawork, Ephrem(Prof.) | |
| dc.contributor.advisor | Aklillu, Eleni(Prof.) | |
| dc.contributor.advisor | Amogne, Wondwessen(PhD) | |
| dc.contributor.author | Tadesse, Wondmagegn Tamiru(PhD) | |
| dc.date.accessioned | 2024-06-12T09:21:47Z | |
| dc.date.available | 2024-06-12T09:21:47Z | |
| dc.date.issued | 2023 | |
| dc.description.abstract | This dissertation reports the results of cross-sectional and case-control studies investigating the prevalence and the link between pharmacogenetic and pharmacokinetic factors with glucose metabolism disorders (GMDs) among patients on efavirenz (EFV) and ritonavir (RTV)- boosted atazanavir (ATV/r)-based combination. GMD status was identified based on fasting glucose, fasting insulin, and HOMA-IR values. Cases were defined as the presence of any impaired fasting glucose, insulin resistance (IR), or diabetes mellitus (DM) while controls were those without GMDs. The cross-sectional prevalence study was conducted on EFV- (n=240) and ATV/r -based (n=111) combination antiretroviral therapy (cART). The prevalence and predictors of GMDs were determined by association and regression analysis. Samples from patients on long-term EFV (75 cases and 165 controls) and ATV/r-based cART (22 cases and 89 controls) were then genotyped for CYP3A4*1B, CYP3A5 (*3 and *6), CYP2B6*6, UGT2B7*2, ABCB1 (c.3435C>T, c.4036A>G), and SLCO1B1 (*1b, *5). The mid-dose (CP12) of EFV, ATV, and RTV plasma concentrations (CP12) was determined using LC-MS/MS. The association of genotypes and CP12 of EFV and ATV/r with the incidence of GMDs were then investigated. vii The prevalence of GMDs for all regimens was 27.6% (97/351) [95% CI 23.0-32.6%], with 31.1% (75/240) [95% CI 25.4-37.5%] for EFV-based and 19.8% (22/111) [95% CI 12.9- 28.5%)] for ATV/r-based cART group. All genotype frequencies followed the Hardy- Weinberg Equilibrium (p>0.05) between cases and controls. In the EFV group, the CYP3A5*6 allele (p = 0.005) and CYP3A5*6 genotype (p = 0.01) were significantly associated with GMD cases. Similarly, multivariate analysis indicated CYP3A haplotype as a significant predictor of GMDs (p = 0.02) and IFG (p = 0.004), while CYP2B6*6 significantly predicted DM (p = 0.03) in EFV-based cART group. Furthermore, EFV Log CP12 ≥ 3.7 (5000) ng/ml was an independent predictor of GMDs. In ATV-based cART-receiving participants, the C allele carriers of SLCO1B1*5 c.521 T>C demonstrated a 2.9 times higher risk of GMDs [AOR=2.9; 95% CI 1.03-8.1, p=0.04] than the wildtype allele carriers. Haplotypes containing any *6 and only *3 of CYP3A conferred 80.0% (p=0.03) and 90.0% (p=0.01) protection, respectively, from GMDs than the wildtype combination haplotypes. In contrast, a 90% protection from IR was recorded for both haplotype combinations containing any *6 (p=0.03) and only *3 (p=0.01) types than the wild-type haplotype combinations. According to the plasma concentration analysis, the mean (SEM) logCP12 of ATV was 3.24 ng/ml (0.04) in controls and 3.52 ng/ml (0.06) in cases. But, the logCP12 of both ATV and RTV failed to show significant association with the GMDs. In conclusion, GMDs are highly prevalent among adults on EFV- than ATV/r-based cARTs. CYP3A haplotype and CYP2B6*6 genotype positively predicted GMDs and DM, respectively, among patients on long-term EFV-based cART. On the other hand, the CYP3A haplotypes decreased and the SLCO1B*5 allele increased the risk of GMDs among PLWH on ATV/r- based regimens. Higher EFV plasma concentration level independently predicted GMDs while viii the ATV plasma concentration did not. Our findings warrant further research with a larger sample size | |
| dc.identifier.uri | https://etd.aau.edu.et/handle/123456789/3156 | |
| dc.language.iso | en_US | |
| dc.publisher | Addis Ababa University | |
| dc.subject | Antiretroviral therapy | |
| dc.subject | efavirenz | |
| dc.subject | atazanavir/ritonavir | |
| dc.subject | glucose metabolic disorder | |
| dc.subject | HIV | |
| dc.subject | pharmacogenetic variation | |
| dc.subject | CYP3A5 | |
| dc.subject | CYP3A4 | |
| dc.subject | CYP2B6 | |
| dc.subject | genotype | |
| dc.subject | drug transporters | |
| dc.subject | single nucleotide polymorphisms | |
| dc.subject | plasma concentration | |
| dc.subject | Ethiopia. | |
| dc.title | Glucose Metabolism Disorders among People Living with HIV/AIDS on Efavirenz and Atazanavir/Ritonavir-Based Combination Antiretroviral Therapy: A Pharmacogenetic and Pharmacokinetic Evaluation | |
| dc.type | Thesis |